Media Contact:
Paula Flavin
Project Marketing Manager
D: 816-912-2000
Email: info@felixvetus.com
Felixvet Receives FDA Approval for Meloxicam Oral Suspension
Kansas City, MO — December 18, 2025 — Felixvet Inc. is proud to expand its growing line of FDA-approved veterinary pharmaceuticals with the approval of Meloxicam Oral Suspension, a prescription NSAID formulated to manage pain and inflammation caused by osteoarthritis in dogs. With an emphasis on therapeutic value and affordability, Felixvet is helping meet the daily clinical needs of veterinarians and the long-term care needs of aging pets.
“Pain relief is essential to quality of life, especially for aging pets,” said Vince Palasota, President of North America at Felixvet. “With the approval of Meloxicam Oral Suspension, we’re providing veterinarians and pet owners with a safe, trusted treatment option backed by rigorous FDA standards.”
Meloxicam Oral Suspension is a prescription NSAID that offers effective relief from osteoarthritis symptoms such as stiffness, decreased mobility and joint pain. While not a cure, the medication helps reduce inflammation and improve overall comfort and activity levels in affected dogs. Clinical results may be seen within days, and daily administration can significantly improve a pet’s quality of life.
The oral suspension is easy to administer, particularly for small dogs, and comes in a 1.5 mg/mL concentration. It includes a dosing syringe for accurate measurement and can be mixed with food or administered directly, depending on the dog’s weight and veterinarian guidance.
“Pet owners are seeking convenient and dependable options to manage chronic pain,” Palasota added. “Meloxicam Oral Suspension delivers on both counts and represents another important step in our expanding portfolio of generic veterinary pharmaceuticals.”
Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.
For more information, email info@felixvetus.com.
About Felixvet:
Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.